What Happened
Novo Nordisk has advanced amycretin into a global Phase 3 program, launching in early 2026. The program is notable for testing both an injectable and an oral formulation of the same compound, a dual-track approach that reflects the company's interest in reaching different segments of the obesity market with a single molecular concept. Moving a candidate into a global Phase 3 is a significant commitment, signaling that earlier data cleared the bar the company set for large-scale investment.
A Single Molecule, Two Targets
Amycretin is a unimolecular agent, meaning one molecule activates two receptors: the GLP-1 receptor and the amylin receptor. That design places it in a growing class of combination approaches, but with the engineering elegance of a single compound rather than a co-formulation of two separate drugs. Combining two mechanisms in one molecule can simplify formulation and dosing relative to pairing two agents, which is part of the appeal of the unimolecular route.
The rationale is mechanistic. GLP-1 signaling is well characterized for its effects on appetite and glucose handling and anchors most of today's obesity therapeutics. Amylin signaling adds a distinct satiety pathway on top of that. By recruiting both, amycretin is designed to layer two complementary routes to reduced food intake within one molecule, on the hypothesis that engaging the two pathways together produces more than either does alone.
The Early Efficacy Signal
A Phase 1b/2a study showed up to about 22% weight loss at 36 weeks. That figure, from an early-stage study, is what positioned amycretin as a serious next-generation candidate and helped justify the move into a full Phase 3 program. As always with early data, the result reflects a specific study population over a defined window and does not establish what larger, longer trials will show. Early efficacy signals in the obesity field have sometimes moderated as trials scale, which is one reason the Phase 3 readouts will be watched closely.
Injectable and Oral in Parallel
Running injectable and oral formulations simultaneously in Phase 3 is a strategic choice. It lets Novo Nordisk evaluate the same dual-receptor concept across two delivery routes, each with its own convenience and adherence profile. The oral track is particularly closely watched, because delivering peptides orally is difficult, a challenge already visible in the strict handling requirements of oral semaglutide. Whether amycretin's oral form can combine the dual-receptor mechanism with workable absorption is one of the more interesting questions the program poses.
Amycretin is being framed as a next-generation candidate positioned after semaglutide. It represents Novo Nordisk's attempt to build on the amylin pathway that also underpins its cagrilintide and CagriSema efforts, but consolidated into one molecule rather than delivered as a co-formulation. That places it alongside a broader wave of amylin-directed research, from petrelintide to a range of Phase 1 amylin candidates.
What It Means
The advance signals that the amylin receptor is becoming a central target in obesity research, not merely an add-on to GLP-1. Whether a single dual-receptor molecule outperforms co-formulated approaches, and whether the oral form can match the injectable, are among the open questions the Phase 3 program is designed to probe. For the field, amycretin is a test of the unimolecular strategy at scale.
Important Note
This article is for educational and research reference purposes only. It does not provide dosing advice for human use. Peptide compounds discussed here are sold for research purposes, and nothing here constitutes medical advice. Approved medications should only be used under physician supervision.